[{"orgOrder":0,"company":"Sino Biopharmaceutical","sponsor":"Inventiva Pharma","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Inventiva Announces that its Partner Sino Biopharm Received IND Approval from the NMPA to initiate Clinical Trial with Lanifibranor in China","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase III","country":"HONG KONG","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III"}]
Find Clinical Drug Pipeline Developments & Deals by Sino Biopharmaceutical
IVA337 (Lanifibranor), is an orally-available small molecule which induces anti-fibrotic, anti-inflammatory and beneficial vascular and metabolic changes in the body by activating all three PPAR isoforms, regulating gene expression.